GENETIC SCREENING REVEALS DEPENDENCY ON FEN1 TO RESIST TEMOZOLOMIDE IN TREATMENT-RESISTANT GLIOBLASTOMA STEM CELLS

BTFC travel award recipient Glioblastoma (GBM) is a lethal brain tumor. Despite intensive standard of care (SoC) consisting of surgical resection followed by radiation therapy (RT) and chemotherapy with temozolomide (TMZ), tumor relapse is inevitable with a median overall survival of 14.6 months. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Brakel, Benjamin, Saleh, Ali, Saleh, Melissa, Miletic, Petar, Salim, Sabra, Maich, William, Brown, Kevin R, Tieu, David, Venugopal, Chitra, Moffat, Jason, Katyal, Sachin, Singh, Sheila K, Chokshi, Chirayu R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Oral Abstract Presentations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337540/
http://dx.doi.org/10.1093/noajnl/vdad071.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337540/
http://dx.doi.org/10.1093/noajnl/vdad071.004

Ejemplares similares